

Neuraminidase inhibitor resistance in influenza viruses

Antiviral Therapy

17, 159-173

DOI: [10.3851/imp2067](https://doi.org/10.3851/imp2067)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Understanding Influenza Virus Resistance to Antiviral Agents; Early Warning Signs for Wider Community Circulation. <i>Journal of Infectious Diseases</i> , 2012, 206, 145-147.	1.9	16
2	Influenza A(H1N1)pdm09: beyond the pandemic. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2012, 30, 54-57.	0.3	5
3	Influenza A(H1N1)pdm09 virus: viral characteristics and genetic evolution. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2012, 30, 10-17.	0.3	13
4	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 1065-1069.	1.3	33
5	Antiviral Agents Against Influenza Viruses. <i>Journal of Bacteriology and Virology</i> , 2012, 42, 284.	0.0	11
6	Glycolytic control of vacuolar-type ATPase activity: A mechanism to regulate influenza viral infection. <i>Virology</i> , 2013, 444, 301-309.	1.1	110
7	In silico study on multidrug resistance conferred by I223R/H275Y double mutant neuraminidase. <i>Molecular BioSystems</i> , 2013, 9, 2764.	2.9	16
8	Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study. <i>Journal of Computer-Aided Molecular Design</i> , 2013, 27, 935-950.	1.3	28
9	Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2210-2221.	1.3	40
10	Cell Culture-Selected Substitutions in Influenza A(H3N2) Neuraminidase Affect Drug Susceptibility Assessment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6141-6146.	1.4	41
11	A comprehensive map of the influenza A virus replication cycle. <i>BMC Systems Biology</i> , 2013, 7, 97.	3.0	97
12	Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance. <i>Antiviral Research</i> , 2013, 100, 520-534.	1.9	107
14	Dancing with chemical formulae of antivirals: A panoramic view (Part 2). <i>Biochemical Pharmacology</i> , 2013, 86, 1397-1410.	2.0	34
15	Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection. <i>Virology</i> , 2013, 435, 92-101.	1.1	58
16	Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. <i>Antiviral Research</i> , 2013, 97, 240-244.	1.9	23
17	Influenza antiviral resistance in the Asia-Pacific region during 2011. <i>Antiviral Research</i> , 2013, 97, 206-210.	1.9	35
18	Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 25-36.	1.5	291
19	Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations. <i>Protein and Cell</i> , 2013, 4, 356-363.	4.8	4

#	ARTICLE	IF	CITATIONS
20	Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. <i>Journal of Clinical Virology</i> , 2013, 57, 5-12.	1.6	27
21	Point-Counterpoint: Is the Era of Viral Culture Over in the Clinical Microbiology Laboratory?. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2-8.	1.8	78
22	Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Isolated from Poultry, Vietnam, 2009â€“2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 1963-1971.	2.0	30
23	Influenza A Virus Entry: Implications in Virulence and Future Therapeutics. <i>Advances in Virology</i> , 2013, 2013, 1-9.	0.5	15
24	Pharmacokinetics of Zanamivir following Intravenous Administration to Subjects with and without Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2967-2971.	1.4	13
25	A Prospective Intervention Study on Higher-Dose Oseltamivir Treatment in Adults Hospitalized With Influenza A and B Infections. <i>Clinical Infectious Diseases</i> , 2013, 57, 1511-1519.	2.9	77
26	Evaluation of Three Influenza Neuraminidase Inhibition Assays for Use in a Public Health Laboratory Setting during the 2011â€“2012 Influenza Season. <i>Public Health Reports</i> , 2013, 128, 75-87.	1.3	15
27	R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses. <i>Emerging Infectious Diseases</i> , 2013, 19, 1521-1524.	2.0	63
28	How to approach and treat viral infections in ICU patients. <i>BMC Infectious Diseases</i> , 2014, 14, 321.	1.3	25
29	Cytokine Storm Plays a Direct Role in the Morbidity and Mortality from Influenza Virus Infection and is Chemically Treatable with a Single Sphingosine-1-Phosphate Agonist Molecule. <i>Current Topics in Microbiology and Immunology</i> , 2014, 378, 129-147.	0.7	68
30	Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011â€“2012: application of the WHO antiviral working group criteria. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 258-265.	1.5	33
31	A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade. <i>Scientifica</i> , 2014, 2014, 1-10.	0.6	37
32	Antiviral Resistance in Influenza Viruses. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 387-408.	0.7	17
33	A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus. <i>Virus Research</i> , 2014, 179, 119-124.	1.1	16
34	A Conformational Restriction in the Influenza A Virus Neuraminidase Binding Site by R152 Results in a Combinational Effect of I222T and H274Y on Oseltamivir Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1639-1645.	1.4	15
35	Within-host influenza dynamics: A small-scale mathematical modeling approach. <i>BioSystems</i> , 2014, 118, 51-59.	0.9	25
36	Fitness Costs for Influenza B Viruses Carrying Neuraminidase Inhibitor-Resistant Substitutions: Underscoring the Importance of E119A and H274Y. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2718-2730.	1.4	41
37	In-silico modelling and identification of a possible inhibitor of H1N1 virus. <i>Asian Pacific Journal of Tropical Disease</i> , 2014, 4, S467-S476.	0.5	5

#	ARTICLE	IF	CITATIONS
38	The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses. <i>Antiviral Research</i> , 2014, 101, 93-96.	1.9	29
39	Development of Novel Potent Orally Bioavailable Oseltamivir Derivatives Active against Resistant Influenza A. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 759-769.	2.9	77
40	Computer-Guided Approach to Access the Anti-influenza Activity of Licorice Constituents. <i>Journal of Natural Products</i> , 2014, 77, 563-570.	1.5	38
41	Antiviral Susceptibility of Variant Influenza A(H3N2)v Viruses Isolated in the United States from 2011 to 2013. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2045-2051.	1.4	29
42	The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice. <i>Antiviral Research</i> , 2014, 109, 110-115.	1.9	6
43	Comparing Clinical Characteristics Between Hospitalized Adults With Laboratory-Confirmed Influenza A and B Virus Infection. <i>Clinical Infectious Diseases</i> , 2014, 59, 252-255.	2.9	104
44	The epidemiology and spread of drug resistant human influenza viruses. <i>Current Opinion in Virology</i> , 2014, 8, 22-29.	2.6	161
45	Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012â€“2013 in Beijing, China. <i>Infection, Genetics and Evolution</i> , 2014, 26, 228-240.	1.0	18
47	Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. <i>Antiviral Therapy</i> , 2014, 20, 415-423.	0.6	8
48	Identification of Novel Compounds against an R294K Substitution of Influenza A (H7N9) Virus Using Ensemble Based Drug Virtual Screening. <i>International Journal of Medical Sciences</i> , 2015, 12, 163-176.	1.1	16
49	Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4137.	2.0	11
50	Clinical Implications of Antiviral Resistance in Influenza. <i>Viruses</i> , 2015, 7, 4929-4944.	1.5	148
51	Ferret models of viral pathogenesis. <i>Virology</i> , 2015, 479-480, 259-270.	1.1	142
52	Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3208-3219.	1.6	19
53	Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. <i>Vaccine</i> , 2015, 33, 7008-7014.	1.7	5
54	Influenza A viruses of swine circulating in the United States during 2009â€“2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes. <i>Antiviral Research</i> , 2015, 117, 10-19.	1.9	15
55	Competitive Fitness of Influenza B Viruses with Neuraminidase Inhibitor-Resistant Substitutions in a Coinfection Model of the Human Airway Epithelium. <i>Journal of Virology</i> , 2015, 89, 4575-4587.	1.5	23
56	Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors. <i>Future Virology</i> , 2015, 10, 77-88.	0.9	23

#	ARTICLE	IF	CITATIONS
57	Peramivir: evidence to support the use of the first approved intravenous therapy for influenza. <i>Future Virology</i> , 2015, 10, 937-948.	0.9	4
58	Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir. <i>Virus Research</i> , 2015, 210, 126-132.	1.1	6
59	Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses. <i>Journal of Virology</i> , 2015, 89, 10891-10900.	1.5	43
60	Characterization of Drug-Resistant Influenza A(H7N9) Variants Isolated From an Oseltamivir-Treated Patient in Taiwan. <i>Journal of Infectious Diseases</i> , 2015, 211, 249-257.	1.9	73
61	Profiling and Characterization of Influenza Virus N1 Strains Potentially Resistant to Multiple Neuraminidase Inhibitors. <i>Journal of Virology</i> , 2015, 89, 287-299.	1.5	54
62	Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. <i>Journal of Medical Virology</i> , 2015, 87, 45-56.	2.5	18
63	Multivalent Effect in Influenza Hemagglutinin-Binding Activity of Sugar-Mimic Peptide. <i>Kobunshi Ronbunshu</i> , 2016, 73, 62-68.	0.2	4
64	Reassortant Eurasian Avian-Like Influenza A(H1N1) Virus from a Severely Ill Child, Hunan Province, China, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 1930-1936.	2.0	39
65	Novel Highly Pathogenic Avian A(H5N2) and A(H5N8) Influenza Viruses of Clade 2.3.4.4 from North America Have Limited Capacity for Replication and Transmission in Mammals. <i>MSphere</i> , 2016, 1, .	1.3	56
66	Persistent Infection of Drug-resistant Influenza A Virus during Chemotherapy for Malignant Lymphoma. <i>Internal Medicine</i> , 2016, 55, 1807-1810.	0.3	0
67	Avian H11 influenza virus isolated from domestic poultry in a Colombian live animal market. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-9.	3.0	19
68	Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects. <i>Antiviral Research</i> , 2016, 134, 144-152.	1.9	12
69	Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background. <i>Journal of Virological Methods</i> , 2016, 237, 192-199.	1.0	7
70	Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor. <i>Journal of Virology</i> , 2016, 90, 10693-10700.	1.5	23
71	Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase. <i>Journal of Chemical Theory and Computation</i> , 2016, 12, 6098-6108.	2.3	20
72	Antiviral drug resistance as an adaptive process. <i>Virus Evolution</i> , 2016, 2, vew014.	2.2	162
73	Design, Synthesis, and Evaluation of 3-((4-(<i>t</i> -butyl)-2-(2-benzylidenehydrazinyl)thiazol-5-yl)methyl)quinolin-2(1 <i>H</i>)-ones as Neuraminidase Inhibitors. <i>Chinese Journal of Chemistry</i> , 2016, 34, 403-411.	2.5	14
74	A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance. <i>Journal of Molecular Biology</i> , 2016, 428, 538-553.	2.0	36

#	ARTICLE	IF	CITATIONS
75	The Path of Least Resistance: Mechanisms to Reduce Influenza's Sensitivity to Oseltamivir. <i>Journal of Molecular Biology</i> , 2016, 428, 533-537.	2.0	1
76	Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain. <i>Clinical Microbiology and Infection</i> , 2016, 22, 564.e1-564.e9.	2.8	18
77	Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing. <i>Microbial Drug Resistance</i> , 2017, 23, 253-260.	0.9	10
78	Prospective Surveillance of Antiviral Resistance in Hospitalized Infants Less than 12 Months of Age with A(H3N2) Influenza Infection and Treated with Oseltamivir. <i>Antiviral Therapy</i> , 2017, 22, 515-522.	0.6	6
79	Human infections with novel reassortant H5N6 avian influenza viruses in China. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-2.	3.0	27
80	Genesis and Dissemination of Highly Pathogenic H5N6 Avian Influenza Viruses. <i>Journal of Virology</i> , 2017, 91, .	1.5	57
81	Finding the right combination antiviral therapy for influenza. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1221-1222.	4.6	8
82	Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. <i>Journal of Infectious Diseases</i> , 2017, 216, S566-S574.	1.9	33
83	Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1139-1152.	2.5	20
84	The pharmacological management of severe influenza infection – existing and emerging therapies™. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 81-95.	1.3	15
85	Antiviral Agents Against Respiratory Viruses. , 2017, , 1318-1326.e2.		11
86	Synthesis and Anti-Influenza Virus Activity of Novel bis(4-chromene-3-carbonitrile) Derivatives. <i>Journal of Heterocyclic Chemistry</i> , 2017, 54, 1854-1862.	1.4	47
87	Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay. <i>Molecules</i> , 2017, 22, 1989.	1.7	23
88	Protective Effect of Panax notoginseng Root Water Extract against Influenza A Virus Infection by Enhancing Antiviral Interferon-Mediated Immune Responses and Natural Killer Cell Activity. <i>Frontiers in Immunology</i> , 2017, 8, 1542.	2.2	40
89	Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases. <i>Frontiers in Microbiology</i> , 2017, 8, 205.	1.5	13
90	Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2. <i>Journal of Clinical Virology</i> , 2018, 102, 1-6.	1.6	3
91	Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014). <i>Journal of Medical Virology</i> , 2018, 90, 844-853.	2.5	6
92	Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice. <i>Journal of Medical Virology</i> , 2018, 90, 1431-1437.	2.5	5

#	ARTICLE	IF	CITATIONS
93	Genetic characterization of influenza A(H3N2) viruses from 2014 to 2017 in Yantai, east of China. <i>Laboratoriums Medizin</i> , 2018, 42, 89-97.	0.1	0
94	Emergence of Eurasian Avian-Like Swine Influenza A (H1N1) Virus from an Adult Case in Fujian Province, China. <i>Virologica Sinica</i> , 2018, 33, 282-286.	1.2	21
95	Interferons: Reprogramming the Metabolic Network against Viral Infection. <i>Viruses</i> , 2018, 10, 36.	1.5	54
96	Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus. <i>Viruses</i> , 2018, 10, 339.	1.5	17
97	Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells. <i>PLoS ONE</i> , 2018, 13, e0197246.	1.1	13
98	Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance. <i>PLoS ONE</i> , 2018, 13, e0200849.	1.1	15
99	Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	162
100	Inactivated Influenza Vaccines. , 2018, , 456-488.e21.		14
101	Naturally occurring mutations in PB1 affect influenza A virus replication fidelity, virulence, and adaptability. <i>Journal of Biomedical Science</i> , 2019, 26, 55.	2.6	14
102	Human infection with a novel reassortant Eurasian-avian lineage swine H1N1 virus in northern China. <i>Emerging Microbes and Infections</i> , 2019, 8, 1535-1545.	3.0	31
103	Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors. <i>Antiviral Research</i> , 2019, 169, 104539.	1.9	11
104	Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1711-1718.	0.9	39
105	Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016. <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 372-381.	1.5	11
106	Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017. <i>BMC Infectious Diseases</i> , 2019, 19, 314.	1.3	24
107	Molecular influenza surveillance at a tertiary university hospital during four consecutive seasons (2012-2016) in Catalonia, Spain. <i>Vaccine</i> , 2019, 37, 2470-2476.	1.7	4
108	Detection and Characterization of Influenza B Virus with Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz493.	0.4	1
109	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. <i>Clinical Infectious Diseases</i> , 2019, 68, e1-e47.	2.9	449
110	<i>In Vitro</i> and <i>In Vivo</i> Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated <i>In Vitro</i> Selection. <i>Journal of Virology</i> , 2019, 93, .	1.5	6

#	ARTICLE	IF	CITATIONS
111	Emergence of an Eurasian avian-like swine influenza A (H1N1) virus from mink in China. <i>Veterinary Microbiology</i> , 2020, 240, 108509.	0.8	9
112	Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza. <i>Trends in Biotechnology</i> , 2020, 38, 360-367.	4.9	37
113	Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus. <i>Nature Communications</i> , 2020, 11, 3418.	5.8	10
114	Emerging HxNy Influenza A Viruses. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a038406.	2.9	30
115	Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	5
116	Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. <i>Communications Biology</i> , 2020, 3, 219.	2.0	8
117	Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea. <i>Virology Journal</i> , 2020, 17, 94.	1.4	9
118	Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017â€“2018 and 2018â€“2019 influenza seasons. <i>Archives of Virology</i> , 2021, 166, 179-189.	0.9	8
119	The H ⁺ -ATPase (V-ATPase): from proton pump to signaling complex in health and disease. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C392-C414.	2.1	71
120	Management of Influenza Virus Infections (Orthomyxoviridae). , 2021, , 160-174.		0
121	Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. <i>Chemical Reviews</i> , 2021, 121, 3238-3270.	23.0	40
124	Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects. , 2017, , 1165-1183.		3
125	An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness. <i>Journal of General Virology</i> , 2018, 99, 292-302.	1.3	11
126	I222 Neuraminidase Mutations Further Reduce Oseltamivir Susceptibility of Indonesian Clade 2.1 Highly Pathogenic Avian Influenza A(H5N1) Viruses. <i>PLoS ONE</i> , 2013, 8, e66105.	1.1	21
127	Molecular Surveillance of Antiviral Drug Resistance of Influenza A/H3N2 Virus in Singapore, 2009-2013. <i>PLoS ONE</i> , 2015, 10, e0117822.	1.1	8
128	Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistanceâ€“Associated Substitutions in Ferrets. <i>PLoS ONE</i> , 2016, 11, e0159847.	1.1	9
129	Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010â€“2015. <i>PLoS ONE</i> , 2018, 13, e0190877.	1.1	7
130	Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14. <i>Eurosurveillance</i> , 2016, 21, .	3.9	12

#	ARTICLE	IF	CITATIONS
152	Lessons from resistance analysis in clinical trials of IV zanamivir. <i>Virus Research</i> , 2023, 325, 199039.	1.1	0
153	Detection of reassortant influenza B strains from 2004 to 2015 seasons in Barcelona (Catalonia,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.1	0
154	Phylogenomic analysis uncovers a 9-year variation of Uganda influenza type-A strains from the WHO-recommended vaccines and other Africa strains. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
159	Inactivated and Recombinant Influenza Vaccines. , 2023, , 514-551.e31.		0